Pfenex Inc. (PFNX) Soars 10.8% on March 11

Pfenex Inc. (PFNX) Soars 10.8% on March 11

Pfenex Inc. (PFNX) had a good day on the market for Monday March 11 as shares jumped 10.8% to close at $4.72. About 196,703 shares traded hands on 1,258 trades for the day, compared with an average daily volume of 81,667 shares out of a total float of 31.46 million. After opening the trading day at $4.40, shares of Pfenex Inc. stayed within a range of $4.75 to $4.31.

With today’s gains, Pfenex Inc. now has a market cap of $148.49 million. Shares of Pfenex Inc. have been trading within a range of $8.42 and $3.13 over the last year, and it had a 50-day SMA of $3.93 and a 200-day SMA of $4.70.

Pfenex is a clinical-stage biotechnology company involved in the development of protein production and bioanalytic technology. The biosimilars portfolio include PF582, for the treatment of patients with retinal diseases; PF530, designed to treat patients with multiple sclerosis; and PF708, to treat osteoporosis patients at high risk of fractures. The vaccine portfolio consists of Px563L, a novel anthrax vaccine candidate to meet U.S. government demand, funded by the U.S. Department of Health and Human Services, through the Biomedical Advanced Research and Development Authority.

Pfenex Inc. is based out of San Diego, CA and has some 65 employees. Its CEO is Evert B. Schimmelpennink.

Scroll Up
error: Content is protected !!